HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.

Abstract
Ovarian clear cell carcinoma is found more often confined to the ovary (stage I) than high-grade serous carcinoma. The RHO GTPase family of proteins is involved in tumor invasion and metastasis through regulation of the cytoskeleton. The expression of several RHO family genes, including RHOA, RHOC, CDC42, and 3 ARHGDIs (Rho GDP dissociation inhibitors), was studied by real-time polymerase chain reaction in 22 clear cell carcinomas and 31 high-grade serous carcinomas. Immunoreaction for p21-activated kinase 1 (a downstream effector of CDC42) was also investigated on 6 tissue microarrays containing 76 carcinomas (13 clear cell carcinomas and 63 high-grade serous carcinomas). Eight clear cell carcinomas (8/21; 38%) were at stage I, whereas only 3 high-grade serous carcinomas (3/31; 10%) were at stage I. Postoperatively, all patients were treated with taxane and cisplatinum or carboplatinum. ARHGDIA messenger RNA expression was higher in clear cell carcinomas than high-grade serous carcinomas (P = .07). In contrast, CDC42 messenger RNA levels were lower in clear cell carcinomas than high-grade serous carcinomas (P = .02). Immunoreaction for p21-activated kinase 1 was concordant with the results obtained by real-time polymerase chain reaction for CDC42. In clear cell carcinomas, RHOA and RHOC messenger RNA expression was lower in stage I than in advanced-stage tumors (P = .03 and P = .005, respectively). Furthermore, in high-grade serous carcinomas, RHOA expression was higher in patients who did not respond to chemotherapy (P = .04). ARHGDIA, CDC42, RHOA, and RHOC expression may contribute to explain the different stage at diagnosis of clear cell and high-grade serous carcinomas. RHOA may cause resistance of high-grade serous carcinoma to chemotherapy.
AuthorsBelen Canet, Cristina Pons, Iñigo Espinosa, Jaime Prat
JournalHuman pathology (Hum Pathol) Vol. 42 Issue 6 Pg. 833-9 (Jun 2011) ISSN: 1532-8392 [Electronic] United States
PMID21208644 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • DNA, Neoplasm
  • GTPase-Activating Proteins
  • Guanine Nucleotide Dissociation Inhibitors
  • RNA, Messenger
  • p21-Activated Kinases
Topics
  • Adenocarcinoma, Clear Cell (drug therapy, genetics, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Biomarkers, Tumor (metabolism)
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous (drug therapy, genetics, pathology)
  • DNA, Neoplasm (analysis)
  • Drug Resistance, Neoplasm
  • Female
  • GTPase-Activating Proteins (genetics, metabolism)
  • Gene Expression Regulation, Neoplastic (physiology)
  • Guanine Nucleotide Dissociation Inhibitors (genetics, metabolism)
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms (drug therapy, genetics, pathology)
  • RNA, Messenger (metabolism)
  • Tissue Array Analysis
  • p21-Activated Kinases (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: